Copywriter salary in Boston

At WHOOP, we're on a mission to unlock human performance. WHOOP empowers our members to perform at a higher level through a deeper understanding of their bodies and daily lives through science-backed research, data and daily habit tracking. As a Copywriter at WHOOP, you will work closely with our marketing team to craft both short-form marketing copy and long-form editorial pieces across multiple channels such as email, social, blog, podcast, and

Who We Are Babylist is the leading digital destination for growing families. For over a decade, Babylist has been the technology solution for expecting parents and the community that supports them, expanding from baby registry into a full-service platform that helps parents make decisions with confidence, stay connected and build happy and healthy families. Every year Babylist helps over 9M people make purchases through its registry, app

DescriptionAs the Content Marketing Contractor at Tufin, you will be responsible for developing and executing content strategies that engage and educate our target audiences. Tufin is a leading network security policy management organization that caters to cybersecurity and network security professionals. You will be responsible for creating compelling and informative content that positions us as a thought leader in the network security policy

THE ROLE: Copywriting Co-Op **This role is for current Northeastern undergrad students only** A Copywriter charged with bringing our brands to life through words. This position will help write and copyedit a broad range of content, including our event titles, daily SMS and push notifications, email subject lines, and more. What you’ll Do... With the guidance of Copywriters, Senior Copywriter, apply Rue La La and Gilt voice to original copy for our

About the Department The Lexington Site is home to a growing Development organization, part of Novo Nordisk following its acquisition of Dicerna Pharmaceuticals, Inc. in December 2021. The Lexington Development team is responsible for leading the clinical advancement of Dicerna's research pipeline of GalXC™ and GalXC-Plus™ RNAi investigational therapies and select candidates from the broader Novo Nordisk portfolio, targeting both rare and